China Resources Double-Crane Pharmaceutical Co., Ltd.SSE: 600062

(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining U.S. FDA Clinical Trial Approval for DC7001A Capsules by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.

· Issued by China Resources Double-Crane Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600062 · · 2 pages · Chinese

Summary by 6ix AI

The company cautions that the drug is still in the early stages of clinical development and carries risks related to safety and efficacy confirmation.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600062china-resources-double-crane-pharmaceutical-co-ltdannouncement-on-obtaining-us-fda-clinical-trial-approval-for-dc7001a-capsules-by-wholly-owned-subsidiary-beijing-double-crane-runchuang-technology-co-ltd

Release

Announcement on Obtaining U.S. FDA Clinical Trial Approval for DC7001A Capsules by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from China Resources Double-Crane Pharmaceutical

Later from China Resources Double-Crane Pharmaceutical

All China Resources Double-Crane Pharmaceutical news releases